Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to Their IND for Treatment of Malignant Glioma

Calidi Biotherapeutics, Inc., announced that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s Phase 1 clinical trial treating brain tumor patients with an engineered oncolytic adenovirus delivered by neural stem cells.